Video

Dr. Kumar Discusses Daratumumab in Multiple Myeloma

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab (Darzalex) in multiple myeloma.

The first monoclonal antibodies have been approved for use in multiple myeloma. Daratumumab, a monoclonal antibody, binds to CD38, which is overexpressed by multiple myeloma cells.

The results seen with daratumumab have been quite striking, says Kumar. There have been 2 large phase III trials, both of which showed adding daratumumab to regularly used regimens improved progression-free survival.

Related Videos
Mark Awad, MD, PhD, chief, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center
Rasha Cosman, BSc, MBBS, FRACP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Nicholas P. McAndrew, MD, MSCE
Xichun Hu, MD, PhD
Nicolas Girard, MD
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB